Search results for "1506"

showing 10 items of 235 documents

Prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication of children and adolescents in Germany: results o…

2012

Objective To investigate the prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication and its associations with socioeconomic status (SES), health-related behaviour and living conditions. Design Observational cross-sectional study. Setting Germany. Participants Representative population-based sample of non-institutionalised youth aged between 0 and 17 years (n=17 450) and examined between 2003 and 2006. Main outcome measure Prevalence and spectrum of ADHD medication (Anatomical Therapeutic Chemical (ATC) code N04BA) measured by standardised computer-assisted personal interview (CAPI) on drug use. Results The overall prevalence of ADHD medication (s…

Pediatricsmedicine.medical_specialtyMultivariate analysisEpidemiologyPopulationPrevalenceLogistic regressionEpidemiologymedicineAttention deficit hyperactivity disorder17231506educationSocioeconomic statuseducation.field_of_studybusiness.industryResearchAtomoxetinePaediatricsGeneral Medicinemedicine.disease16921712Public Healthbusiness1719medicine.drugBMJ Open
researchProduct

Sociodemographic factors associated with time to discharge for hospitalised patients with asthma and asthma exacerbation using the Ghana Health Servi…

2021

ObjectiveData on asthma hospitalisations are a useful source of patient morbidity information. In Ghana, the length of stay (LoS) and sociodemographic factors of patients hospitalised for asthma and its exacerbation are understudied. We aimed to investigate the time to discharge and assessed factors associated with length of hospital stays of asthmatics in Ghana.MethodsRetrospective analysis of hospitalised patient with asthma records between 2012 and 2017 from the nationwide Ghana Health Service District Health Information Management System 2 database. We calculated the cumulative incidence function for discharge stratified by age group and sex. Multivariable Cox regression was used to inv…

Pulmonary and Respiratory MedicineAdultSociodemographic FactorsExacerbationInformation Managementcomputer.software_genreGhanaHealth servicesDiseases of the respiratory systemHealth caremedicineHumans1506ChildEarly dischargeAsthmaRetrospective StudiesAsthma exacerbationsDatabaseRC705-779business.industryProportional hazards modelasthma epidemiologyRmedicine.diseaseComorbidityAsthmaPatient DischargeCOPD exacerbationsMedicineFemalebusinesscomputerBMJ Open Respiratory Research
researchProduct

Coil embolisation for massive haemoptysis in cystic fibrosis.

2021

IntroductionMassive haemoptysis is a life-threatening event in advanced cystic fibrosis (CF) lung disease with bronchial artery embolisation (BAE) as standard of care treatment. The aim of our study was to scrutinise short-term and long-term outcomes of patients with CF and haemoptysis after BAE using coils.MethodsWe carried out a retrospective cohort study of 34 adult patients treated for massive haemoptysis with super selective bronchial artery coil embolisation (ssBACE) between January 2008 and February 2015. Embolisation protocol was restricted to the culprit vessel(s) and three lobes maximum. Demographic data, functional end-expiratory volume in 1 s in % predicted (FEV1% pred.) and bod…

Pulmonary and Respiratory MedicineAdultmassive haemoptysismedicine.medical_specialtyHemoptysisCystic FibrosisMedizinBronchial ArteriesCulpritCystic fibrosisDiseases of the respiratory systemmedicine.arterymedicineHumansIn patient22181506Coil embolizationRetrospective StudiesRC705-779business.industryRRetrospective cohort studymedicine.diseaseEmbolization TherapeuticSurgeryMedicineSputummedicine.symptomBronchial arterybusinessBody mass indexBMJ open respiratory research
researchProduct

Against all odds: anti-IgE for intrinsic asthma?

2013

For many years, pathogenetic concepts and the results of clinical trials supported the view that anti-IgE treatment is specifically effective in allergic asthma. However, there is now growing clinical and mechanistic evidence suggesting that treatment with the anti-IgE antibody omalizumab can be effective in patients with intrinsic asthma. Therefore, large and well-controlled clinical trials with anti-IgE are urgently warranted in patients with intrinsic asthma. In addition, there is a need to find new biomarkers which can identify patients with asthma who respond to anti-IgE treatment.

Pulmonary and Respiratory MedicineIntrinsic FactorChest ClinicOmalizumabOmalizumabAsthma PharmacologyImmunoglobulin EAntibodies Monoclonal HumanizedAnti-asthmatic AgentOddsmedicineHumansAnti-Asthmatic Agents1506AsthmaIntrinsic factorbiologybusiness.industrymedicine.diseaseAsthmaImmunity Innaterespiratory tract diseasesAntibodies Anti-IdiotypicClinical trialAsthma MechanismsIntrinsic asthmaImmunologybiology.proteinDisease Progressionbusinessmedicine.drugThorax
researchProduct

Authors' response to: epithelial mesenchymal transition (EMT) in small airways of COPD patient.

2013

We understand the reservations highlighted by Sohal and Walters in their letter in response to our recent work published.1 In their letter, Sohal and Walters argue that E-cadherin and ZO-1 are absent in our immunohistochemistry analysis of small bronchi of smokers and COPD patients, and that if disappeared completely epithelium would fall apart.1 In our study, we detected downregulation of E-cadherin and ZO-1 as well as a change of intercellular and apical distribution to diffuse cytoplasmic redistribution (figure 3B; in our work published in Thorax on 7 January 2013),2 but not …

Pulmonary and Respiratory MedicineMalePathologymedicine.medical_specialtyEpithelial-Mesenchymal TransitionCopd patientsCOPD PathologyBronchiPulmonary Disease Chronic ObstructiveDownregulation and upregulationAirway EpitheliumSmokemedicineHumansEpithelial–mesenchymal transition1506COPDSmall airwaysbusiness.industrySmokingEpithelial CellsPostScriptmedicine.diseaseEpitheliumrespiratory tract diseasesmedicine.anatomical_structureRespiratory epitheliumImmunohistochemistryFemalebusinessThorax
researchProduct

Aclidinium inhibits human lung fibroblast to myofibroblast transition

2011

Background Fibroblast to myofibroblast transition is believed to contribute to airway remodelling in lung diseases such as asthma and chronic obstructive pulmonary disease. This study examines the role of aclidinium, a new long-acting muscarinic antagonist, on human fibroblast to myofibroblast transition. Methods Human bronchial fibroblasts were stimulated with carbachol (10 −8 to 10 −5  M) or transforming growth factor-β1 (TGF-β1; 2 ng/ml) in the presence or absence of aclidinium (10 −9 to 10 −7  M) or different drug modulators for 48 h. Characterisation of myofibroblasts was performed by analysis of collagen type I and α-smooth muscle actin (α-SMA) mRNA and protein expression as well as α…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCarbacholChronic Obstructive Pulmonary DiseaseBronchiMuscarinic AntagonistsBiologyCholinergic AgonistsCollagen Type ITransforming Growth Factor beta1Downregulation and upregulationWestern blotanticholinergicCell MovementInternal medicinemedicineCOPDHumans1506RNA MessengerAutocrine signallingFibroblastMyofibroblastsCells CulturedCell Proliferationmedicine.diagnostic_testDose-Response Relationship Drugairway epitheliumCell Differentiationasthmainterstitial fibrosisFibroblastsAdenosineMolecular biologymyofibroblastActinsUp-RegulationEndocrinologymedicine.anatomical_structurePhosphorylationFibroblastCarbacholMyofibroblastmedicine.drugTropanesThorax
researchProduct

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD

2020

This exploratory, randomised, double-blind, double-dummy, multicentre, cross-over study explored the effect of 6 weeks of treatment with tiotropium/olodaterol (T/O) versus fluticasone propionate/salmeterol (F/S) on left ventricular filling in patients with chronic obstructive pulmonary disease with functional residual capacity (FRC) >120% predicted and postbronchodilator improvement of FRC ≥7.5%. Overall, 76 patients were randomised across nine sites. Treatment with T/O or F/S increased left ventricular end-diastolic volume index from baseline (adjusted mean change: T/O: 2.317 mL/m2, F/S: 2.855 mL/m2), with no statistically significant difference between treatments. However, T/O resulted…

Pulmonary and Respiratory Medicinemedicine.medical_specialtylcsh:MedicineFluticasone propionatePulmonary Disease Chronic Obstructive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFunctional residual capacityInternal medicinemedicineHumansMulticenter Studies as TopicPlethysmographIn patient1506030212 general & internal medicineTiotropium BromideLunginhaler devicesRandomized Controlled Trials as Topiclcsh:RC705-779COPDCross-Over Studiesbusiness.industrylcsh:ROlodaterollcsh:Diseases of the respiratory systemrespiratory systemmedicine.diseaseFluticasone-Salmeterol Drug CombinationBenzoxazinesBronchodilator Agentsrespiratory tract diseasesrespiratory measurement030228 respiratory systemchemistryPerspectiveCardiologyCOPD pharmacologySalmeterolVentricular fillingbusinessmedicine.drugBMJ Open Respiratory Research
researchProduct

Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfu…

2015

Objective Conflicting evidence exists on the benefits of treating patients with coronary artery disease and preserved left ventricular ejection fraction (LVEF) with an ACE inhibitor. This retrospective analysis of the SMILE-4 Study sought to compare the efficacy of zofenopril 60 mg plus acetylsalicylic acid (ASA) versus ramipril 10 mg plus ASA 100 mg in patients with acute myocardial infarction (AMI) and heart failure, according to an impaired or preserved LVEF. Methods The primary study end point was 1-year combined occurrence of death or hospitalisation for cardiovascular causes. A preserved LVEF was defined by a baseline LVEF >40% and an impaired one by an LVEF ≤40%. Results 448 patients…

Ramiprilmedicine.medical_specialtyacute myocardial infarctionInfarctionramiprilCoronary Artery DiseaseCoronary artery diseasechemistry.chemical_compoundInternal medicinemedicinezofenopril1506cardiovascular diseasesMyocardial infarctionleft ventricular dysfunctionEjection fractionbusiness.industryleft ventricular ejection fractionmedicine.diseaseZofenoprilangiotensin-converting enzyme inhibitorsangiotensin-converting enzyme inhibitorchemistryacute myocardial infarction; angiotensin-converting enzyme inhibitors; left ventricular dysfunction; left ventricular ejection fractionHeart failureACE inhibitorcardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologyBiomedical engineeringmedicine.drugOpen Heart
researchProduct

Rethinking the role of fat oxidation: substrate utilisation during high-intensity interval training in well-trained and recreationally trained runners

2015

Background Although carbohydrate is the predominant fuel source supporting high-intensity exercise workloads, the role of fat oxidation, and the degree to which it may be altered by training status, is less certain. Methods We compared substrate oxidation rates, using indirect calorimetry, during a high-intensity interval training (HIT) session in well-trained (WT) and recreationally trained (RT) runners. Following preliminary testing, 9 WT (VO2max 71±5 mL/min/kg) and 9 RT (VO2max 55±5 mL/min/kg) male runners performed a self-paced HIT sequence consisting of six, 4 min work bouts separated by 2 min recovery periods on a motorised treadmill set at a 5% gradient. Results WT and RT runners per…

Rating of perceived exertionPhysiologyChemistryResearchCarbohydratesSubstrate (chemistry)Physical Therapy Sports Therapy and RehabilitationCarbohydrate metabolismCarbohydrateInterval trainingConfidence intervalMetabolismAnimal scienceFatTrainingOrthopedics and Sports Medicine1506TreadmillHigh-intensity interval trainingBMJ Open Sport & Exercise Medicine
researchProduct

Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort…

2015

Objective: To investigate the relationship between Ankle-Brachial Index (ABI) and renal function progression in patients with atrial fibrillation (AF). Design: Observational prospective multicentre cohort study. Setting: Atherothrombosis Center of I Clinica Medica of 'Sapienza' University of Rome; Department of Medical and Surgical Sciences of University Magna Græcia of Catanzaro; Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. Participants: 897 AF patients on treatment with vitamin K antagonists. Main outcome measures: The relationship between basal ABI and renal function progression, assessed by the estimated Glomerular Filtration R…

RegistrieMaleAnkle brachial index atrial fibrillation renal functionCross-sectional studyAngiotensin-Converting Enzyme InhibitorsBlood PressureCardiovascular Medicineurologic and male genital diseasesKidneyRisk FactorsAtrial FibrillationOdds RatioSurveys and Questionnaireatrial fibrillation1506Prospective StudiesRenal InsufficiencyPractice Patterns Physicians'Prospective cohort studyMedicine (all)Atrial fibrillationGeneral MedicineMiddle Agedmedicine.anatomical_structureItalyHypertensioncardiovascular systemCardiologyDisease ProgressionFemaleVitamin K antagonistABICohort studyHumanGlomerular Filtration RateAnkle brachial index; atrial fibrillation; renal function1683medicine.medical_specialtyLogistic ModelNon-Vitamin K oral anticoagulantRenal functionrenal function declineAnkle-Brachial IndexNOInternal medicineAged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Cross-Sectional Studies; Disease Progression; Female; Humans; Hypertension; Italy; Kidney; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Renal Insufficiency; Risk Factors; Ankle Brachial Index; Blood Pressure; Glomerular Filtration Rate; Medicine (all)medicineInternal MedicineHumansAnkle Brachial Indexcardiovascular diseasesIntensive care medicineAgedCross-Sectional StudieAntithrombotic therapybusiness.industryRisk FactorResearchrenal functionAnticoagulantAngiotensin-Converting Enzyme InhibitorOdds ratiomedicine.diseasebody regionsProspective StudieBlood pressureAtrial fibrillation; Ankle-Brachial Index; renal function declineCross-Sectional StudiesLogistic ModelsAnklebusinessABI renal function atrial fibrillation
researchProduct